These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37601856)

  • 1. Selinexor: Targeting a novel pathway in multiple myeloma.
    Mo CC; Yee AJ; Midha S; Hartley-Brown MA; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
    EJHaem; 2023 Aug; 4(3):792-810. PubMed ID: 37601856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
    Richard S; Jagannath S
    BioDrugs; 2022 Jan; 36(1):13-25. PubMed ID: 35113384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
    Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
    Onco Targets Ther; 2020; 13():6405-6416. PubMed ID: 32669858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
    Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e526-e531. PubMed ID: 35361554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
    J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
    Masood A; Iqbal Q; Ehsan H; Davis JA; Hansen DK; Hashmi H
    Ann Hematol; 2022 Dec; 101(12):2601-2610. PubMed ID: 36214853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
    Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
    Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
    Syed YY
    Target Oncol; 2023 Mar; 18(2):303-310. PubMed ID: 36622630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor for the treatment of patients with previously treated multiple myeloma.
    Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
    Expert Rev Hematol; 2021 Aug; 14(8):697-706. PubMed ID: 33985401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
    Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
    Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
    Ehsan H; Robinson M; Voorhees PM; Cassetta K; Borden S; Atrash S; Bhutani M; Varga C; Pineda-Roman M; Friend R; Paul BA
    Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.
    Muz B; Azab F; de la Puente P; Landesman Y; Azab AK
    Transl Oncol; 2017 Aug; 10(4):632-640. PubMed ID: 28668761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selinexor for the treatment of multiple myeloma.
    Podar K; Shah J; Chari A; Richardson PG; Jagannath S
    Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
    N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB.
    Galinski B; Luxemburg M; Landesman Y; Pawel B; Johnson KJ; Master SR; Freeman KW; Loeb DM; Hébert JM; Weiser DA
    Transl Oncol; 2021 Aug; 14(8):101114. PubMed ID: 33975179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.
    Tao Y; Zhou H; Niu T
    Front Pharmacol; 2021; 12():758992. PubMed ID: 34925019
    [No Abstract]   [Full Text] [Related]  

  • 20. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
    BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.